Horizon Therapeutics (HZNP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 204,261 | 534,491 | 361,309 | 34,766 | -123,351 |
| Depreciation Amortization | 96,689 | 358,940 | 260,956 | 164,976 | 71,593 |
| Income taxes - deferred | -33,896 | -101,016 | -147,934 | -18,115 | -28,771 |
| Accounts receivable | -51,665 | 34,796 | -107,776 | -68,014 | 224,575 |
| Accounts payable and accrued liabilities | 36,067 | -12,197 | 7,640 | 10,306 | 993 |
| Other Working Capital | -101,753 | -61,740 | -203,388 | -264,962 | 8,704 |
| Other Operating Activity | 66,088 | 281,997 | 325,907 | 226,717 | -157,471 |
| Operating Cash Flow | $215,791 | $1,035,271 | $496,714 | $85,674 | $-3,728 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -14,198 | -74,596 | -57,695 | -32,255 | -18,333 |
| Net Acquisitions | -3,122 | -2,843,275 | -2,843,275 | -2,775,330 | -2,707,358 |
| Purchase Of Investment | -1,464 | -28,256 | -13,385 | -11,473 | -3,808 |
| Sale Of Investment | 3,060 | 3,588 | 3,588 | 3,895 | N/A |
| Purchase Sale Intangibles | -25,000 | -51,572 | -46,500 | N/A | N/A |
| Other Investing Activity | -25,000 | -51,572 | -46,500 | 0 | 0 |
| Investing Cash Flow | $-40,724 | $-2,994,111 | $-2,957,267 | $-2,815,163 | $-2,729,499 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 1,574,993 | 1,574,993 | 1,574,993 | 1,577,612 |
| Debt Repayment | -4,000 | -12,000 | -8,000 | -4,000 | N/A |
| Common Stock Issued | 9,071 | 73,094 | 51,495 | 39,321 | 19,843 |
| Other Financing Activity | -115,108 | -165,964 | -158,077 | -141,648 | -128,261 |
| Financing Cash Flow | $-110,037 | $1,470,123 | $1,460,411 | $1,468,666 | $1,469,194 |
| Exchange Rate Effect | -1,921 | -10,606 | -10,951 | -6,498 | -3,998 |
| Beginning Cash Position | 1,584,156 | 2,083,479 | 2,083,479 | 2,083,479 | 2,083,479 |
| End Cash Position | 1,647,265 | 1,584,156 | 1,072,386 | 816,158 | 815,448 |
| Net Cash Flow | $63,109 | $-499,323 | $-1,011,093 | $-1,267,321 | $-1,268,031 |
| Free Cash Flow | |||||
| Operating Cash Flow | 215,791 | 1,035,271 | 496,714 | 85,674 | -3,728 |
| Capital Expenditure | -14,198 | -76,596 | -59,695 | -32,255 | -18,333 |
| Free Cash Flow | 201,593 | 958,675 | 437,019 | 53,419 | -22,061 |